Form 8-K - Current report:
SEC Accession No. 0001104659-25-059362
Filing Date
2025-06-13
Accepted
2025-06-13 16:15:23
Documents
12
Period of Report
2025-06-12
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517990d1_8k.htm   iXBRL 8-K 26183
  Complete submission text file 0001104659-25-059362.txt   194384

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rnaz-20250612.xsd EX-101.SCH 3053
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rnaz-20250612_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rnaz-20250612_pre.xml EX-101.PRE 22384
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2517990d1_8k_htm.xml XML 3799
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40363 | Film No.: 251046760
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)